[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.159.129.152. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Article
August 1986

Calmodulin Inhibitor Therapy in Psoriasis

Author Affiliations

Department of Dermatology Centre Hospitalier Universitaire 2 Place St Jacques 25-3-Besançon Cedex, France

Arch Dermatol. 1986;122(8):856-857. doi:10.1001/archderm.1986.01660200024007
Abstract

To the Editor.—  Calmodulin, an intracellular calcium receptor protein, activates some enzymes such as adenylcyclase, phosphodiesterase, and phospholipase A2. It has been reported that active calmodulin levels are elevated in the skin of psoriatic patients.1,2 Moreover, a recent study shows a generalized increase in activity of phospholipase A2 in psoriatic skin.3 Such observations could be of great importance in elucidating the pathogenesis of psoriasis, some of the features of psoriasis (cell proliferation and cell diviClinical Results* Erythema Scaling Thickness Pruritus Cumulative Score Differential Score Chlorpromazine group Before M 2.73 SEM After M SEM 0.22 1.13 0.19 2.53 0.19 0.66 0.23 2.06 0.18 0.60 0.19 1.53 0.33 0.60 0.28 8.86 0.72 3.86 0.98 M = 5.00 SEM = 0.79 Placebo group Before M SEM After M SEM 3.05 0.09 2.88 0.11 2.94 0.15 2.11 0.17 2.38 0.11 2.11 0.11 1.11 0.25 0.38 0.11 9.50 0.42 7.55 0.30 M = 1.94

First Page Preview View Large
First page PDF preview
First page PDF preview
×